Polyplus-transfection and Blue Sky BioServices sign a research and commercial license agreement for use of PEI-based transfection technologies
Polyplus-transfection SA and Blue Sky BioServices announced a non-exclusive, research and commercial license agreement. Polyplus has granted Blue Sky BioServices a licence to use Polyethylenimine (PEI) for in vitro transfection applications.
Blue Sky BioServices, has become the 17th sub-licensee, and the 4th CRO to acquire rights from Polyplus to use its PEI-mediated transfection applications for research and commercial purposes. Financial terms were not disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Imaging Biomarkers

Hematopoietic stem cells: Why don't pregnant women become anemic?
Signaling Continued Investment in China, Bruker Open Beijing Center of Excellence
Synthon announces European approvals for Eplerenone
Daboia_russelii_siamensis
Category:Leukodystrophies
Cyntellect Appoints Drs. Alan Aderem, Charles Cantor and Michael Hanley to Its Scientific Advisory Board - New members to foster expanded applications of cell-based manipulation from functional proteomics to stem cells
